[{"data":1,"prerenderedAt":429},["ShallowReactive",2],{"tool-healthcare-yidu":3,"footer-total":402,"related-healthcare-yidu":403},{"id":4,"title":5,"author":6,"bestFor":7,"body":8,"category":360,"cons":361,"cover":367,"date":368,"description":369,"draft":370,"extension":371,"meta":372,"navigation":373,"notFor":374,"path":375,"pricing":376,"pros":380,"region":386,"score":387,"scoreBreakdown":388,"seo":394,"stem":395,"tags":396,"toolName":226,"updated":368,"url":399,"vendor":400,"__hash__":401},"tools\u002Ftools\u002Fhealthcare\u002Fyidu.md","医渡科技 评测","元析评测","有科研产出压力、要把病历数据变成可分析资产的三甲医院,以及做上市后研究的药企",{"type":9,"value":10,"toc":332},"minimark",[11,15,23,26,29,66,69,74,77,80,83,86,89,92,95,98,101,104,107,111,114,118,121,125,128,132,135,139,142,145,209,212,215,289,295,299,303,306,310,313,317,320,323,326],[12,13,14],"h2",{"id":14},"结论先行",[16,17,18,22],"p",{},[19,20,21],"strong",{},"有条件推荐,总分 7.6,官网未公开报价,只能项目制谈。"," 医渡科技做的是医院里最脏最累的那段活:把 HIS、LIS、PACS 里格式各异的病历,抽成能筛队列、能跑统计的结构化数据。这一段没有捷径,靠的是病种模板和人工校对堆出来的经验。",[16,24,25],{},"它的边界也很清楚。它不做 HIS,不做通用报表,不给小预算项目开门。如果你的诉求是\"下周给院长看一张门诊量趋势图\",找它属于用错工具;如果诉求是\"三年内出五个专病队列和两篇真实世界研究\",它才对得上。",[12,27,28],{"id":28},"这篇评测基于什么数据",[30,31,32,39,45,51,60],"ul",{},[33,34,35,38],"li",{},[19,36,37],{},"官网",":2026-11 访问 yiducloud.com.cn,首页只返回站点标题与少量文本,产品页返回 403 状态码。我们没能取得产品清单正文与任何价格信息,这一点如实记录。",[33,40,41,44],{},[19,42,43],{},"公开资料",":公司成立于 2014 年,2021 年初在港交所上市;业务分医院与监管侧的数据平台、药企与器械侧的生命科学服务、以及保险与患者侧的健康管理三块。",[33,46,47,50],{},[19,48,49],{},"合规口径",":《个人信息保护法》自 2021-11-01 施行,《数据安全法》自 2021-09-01 施行;涉及人类遗传资源的临床研究按《人类遗传资源管理条例》办理备案或审批。这三条决定了医疗数据平台的作业方式。",[33,52,53,56,59],{},[19,54,55],{},"技术标准",[57,58],"icd-10",{}," 与 ICD-9-CM-3 编码、HL7 FHIR 交换规范、OMOP CDM 通用数据模型,是医疗数据治理绕不开的对接标准。",[33,61,62,65],{},[19,63,64],{},"实测声明",":我们没有使用过它的平台,没有跑过数据治理流程,也没有拿到过项目报价。以下判断来自公开资料与同类项目的普遍规律。",[12,67,68],{"id":68},"核心功能",[70,71,73],"h3",{"id":72},"数据治理把病历变成字段","数据治理:把病历变成字段",[16,75,76],{},"医院的原始数据长这样:同一个检验项目在三年里有四种写法,诊断编码有新老两版并存,病程记录是自由文本。数据治理要做的是把这些归一:建立术语映射、抽取结构化字段、处理缺失与矛盾值。",[16,78,79],{},"这一段的工作量常被低估。一个病种从原始数据到可用队列,通常要经过术语对齐、规则抽取、人工抽检、医生确认四轮。平台能加速,但替代不了医生判断。",[70,81,82],{"id":82},"专病库与科研平台",[16,84,85],{},"专病库按病种建模:以肺癌为例,要纳入分期、病理类型、基因突变、治疗方案、疗效评价、随访结局这些字段。建好之后,研究者能按条件筛队列,比如\"ⅢA 期、EGFR 突变、用过三代 TKI、随访满 24 个月\"。",[16,87,88],{},"科研平台在这之上提供统计分析与数据导出。对三甲医院来说,价值在于把\"想做个回顾性研究\"从半年缩短到几周;但发文章的关键仍在研究设计,工具只解决数据。",[70,90,91],{"id":91},"真实世界研究",[16,93,94],{},"药企侧的活更偏服务:上市后疗效与安全性研究、医保准入的证据准备、医生处方行为的观察性研究。这类研究的数据来源常常横跨多家医院,需要统一口径后再汇总。",[16,96,97],{},"难点在合规。多中心研究涉及数据出境、人类遗传资源备案、伦理审查三道关,任何一道没过,数据就不能动。平台方在这块的经验,实际价值比算法高。",[70,99,100],{"id":100},"区域健康大数据",[16,102,103],{},"面向卫健委与医保局的项目,把区域内多家机构的数据汇到一处,做疾病谱分析、资源配置评估、监管指标监测。这类项目的成败往往不在技术,在协调:十几家医院的数据标准不一致,谁来定口径、谁来签字,比写代码难。",[12,105,106],{"id":106},"评分明细",[70,108,110],{"id":109},"功能完整度8210","功能完整度:8.2\u002F10",[16,112,113],{},"数据治理、专病库、科研分析、真实世界研究、区域平台五块都在,病种模板积累是它的护城河。扣分在通用能力:运营报表、实时大屏、临床决策支持这些不在主推范围。",[70,115,117],{"id":116},"易用性6910","易用性:6.9\u002F10",[16,119,120],{},"平台面向的是统计师和科研助理,不是普通医生。队列筛选的条件组合要学,字段口径要看文档。医院如果没人专职维护,交付半年后基本闲置。",[70,122,124],{"id":123},"数据质量8610","数据质量:8.6\u002F10",[16,126,127],{},"全场最高分。术语映射、编码归一、抽检机制这套东西是它吃饭的本事,治理后的数据能直接进统计软件。扣分在时效:治理成果需要定期重跑,院方不配合就会滞后。",[70,129,131],{"id":130},"性价比6710","性价比:6.7\u002F10",[16,133,134],{},"门槛高是主要问题。项目起订规模决定了中小医院根本进不来,而大医院又要为\"平台加服务\"的混合报价做预算科目拆分。单看软件授权不贵,加上服务就上去了。",[70,136,138],{"id":137},"客户支持7510","客户支持:7.5\u002F10",[16,140,141],{},"项目有专职团队,交付期驻场,验收标准写得比较细。扣分在售后:平台交付后的持续运营支持偏弱,院方遇到字段口径问题常常要等版本更新。",[12,143,144],{"id":144},"定价说明",[146,147,148,164],"table",{},[149,150,151],"thead",{},[152,153,154,158,161],"tr",{},[155,156,157],"th",{},"项目",[155,159,160],{},"价格",[155,162,163],{},"说明",[165,166,167,179,189,199],"tbody",{},[152,168,169,173,176],{},[170,171,172],"td",{},"数据平台与治理",[170,174,175],{},"未公开",[170,177,178],{},"按数据范围、病种数量、院区规模项目制报价",[152,180,181,184,186],{},[170,182,183],{},"专病库建设",[170,185,175],{},[170,187,188],{},"按病种计价,含字段设计与历史数据回溯",[152,190,191,194,196],{},[170,192,193],{},"真实世界研究服务",[170,195,175],{},[170,197,198],{},"按研究方案、中心数量、随访年限计价",[152,200,201,204,206],{},[170,202,203],{},"区域平台",[170,205,175],{},[170,207,208],{},"政府项目招标,含实施与运维",[16,210,211],{},"2026-11 核对时,官网没有任何金额,产品页也打不开。这类项目的报价通常把软件与服务混在一起,医院做预算时要主动要求拆开:平台授权多少钱、每个专病库多少钱、研究服务按什么口径计。拆不开的报价,第二年续费时没有谈判依据。",[12,213,214],{"id":214},"和竞品对比",[146,216,217,233],{},[149,218,219],{},[152,220,221,224,227,230],{},[155,222,223],{},"维度",[155,225,226],{},"医渡科技",[155,228,229],{},"零氪科技",[155,231,232],{},"森亿智能",[165,234,235,249,261,275],{},[152,236,237,240,243,246],{},[170,238,239],{},"定位",[170,241,242],{},"数据治理加真实世界研究",[170,244,245],{},"肿瘤真实世界数据",[170,247,248],{},"临床数据与智能应用",[152,250,251,254,257,259],{},[170,252,253],{},"起步价",[170,255,256],{},"未公开,项目制",[170,258,256],{},[170,260,256],{},[152,262,263,266,269,272],{},[170,264,265],{},"强项",[170,267,268],{},"病种覆盖广、区域项目多",[170,270,271],{},"肿瘤专科深度、药企资源",[170,273,274],{},"病历结构化、临床辅助",[152,276,277,280,283,286],{},[170,278,279],{},"短板",[170,281,282],{},"通用报表弱、门槛高",[170,284,285],{},"专科面窄",[170,287,288],{},"大项目交付经验偏少",[16,290,291,294],{},[19,292,293],{},"怎么选",":要做多病种的科研平台、还想兼顾区域监管项目,医渡科技覆盖面最宽;只做肿瘤方向、主要服务药企,零氪科技的专科数据更细;想把病历结构化后直接嵌进临床流程做质控,森亿智能的产品形态更贴。",[12,296,298],{"id":297},"faq","FAQ",[70,300,302],{"id":301},"q-医院把数据交给厂商合规吗","Q: 医院把数据交给厂商,合规吗?",[16,304,305],{},"A: 取决于交付形态。数据不出院、平台部署在院内、厂商只提供工具与驻场服务,是风险最低的一种;数据要出院的,必须做去标识化并签数据处理协议,涉及人类遗传资源的还要备案。合同里把数据权属、使用边界、销毁义务写清楚,比事后追责有用。",[70,307,309],{"id":308},"q-真实世界研究的结果药监部门认吗","Q: 真实世界研究的结果,药监部门认吗?",[16,311,312],{},"A: 认,但有条件。国家药监局对真实世界证据有专门指导原则,要求数据来源可靠、研究设计合理、偏倚控制到位。真实世界研究目前更多用于支持说明书修订与临床评价,不能替代随机对照试验作为上市审批的主要证据。",[70,314,316],{"id":315},"q-建专病库之前医院要准备什么","Q: 建专病库之前,医院要准备什么?",[16,318,319],{},"A: 三件事:一是确定病种和牵头科室,没有临床负责人,字段设计一定跑偏;二是拿到伦理批件,涉及患者数据的回顾性研究也要过伦理;三是安排数据管理员,通常 1 到 2 人,负责口径确认与抽检。缺第三项,项目验收后就没人维护了。",[12,321,322],{"id":322},"评测方法说明",[16,324,325],{},"元析评测围绕功能完整度、易用性、数据质量、性价比、客户支持五个维度打分,每项满分 10 分,加权折算总分。本篇信息核对于 2026-11,厂商官网首页仅返回少量文本、产品页返回 403,因此不含任何金额与完整产品清单;实际范围与报价以项目方案和合同为准。",[16,327,328,331],{},[19,329,330],{},"最后更新",":2026-11-16",{"title":333,"searchDepth":334,"depth":334,"links":335},"",2,[336,337,338,345,352,353,354,359],{"id":14,"depth":334,"text":14},{"id":28,"depth":334,"text":28},{"id":68,"depth":334,"text":68,"children":339},[340,342,343,344],{"id":72,"depth":341,"text":73},3,{"id":82,"depth":341,"text":82},{"id":91,"depth":341,"text":91},{"id":100,"depth":341,"text":100},{"id":106,"depth":334,"text":106,"children":346},[347,348,349,350,351],{"id":109,"depth":341,"text":110},{"id":116,"depth":341,"text":117},{"id":123,"depth":341,"text":124},{"id":130,"depth":341,"text":131},{"id":137,"depth":341,"text":138},{"id":144,"depth":334,"text":144},{"id":214,"depth":334,"text":214},{"id":297,"depth":334,"text":298,"children":355},[356,357,358],{"id":301,"depth":341,"text":302},{"id":308,"depth":341,"text":309},{"id":315,"depth":341,"text":316},{"id":322,"depth":334,"text":322},"healthcare",[362,363,364,365,366],"官网信息稀薄,首页只给出口号,产品页返回 403,采购前几乎拿不到书面材料","项目制交付,金额门槛高,几十万预算的科室级需求很难立项","平台交付后医院要有人会用,数据治理成果依赖院方持续维护,否则半年就过期","科研服务与软件销售混在一起报价,预算科目不好拆,财务审计时要解释半天","不提供通用 BI 报表能力,日常运营看板还得另找工具",null,"2026-11-16","医渡科技评测:官网未公开报价,项目制签约,主做医疗数据治理、专病库和真实世界研究。适合要建科研平台的医院和做上市后研究的药企,不适合想买现成报表工具或小预算试水的团队。",false,"md",{},true,"只想要几张运营报表的医院信息科,或预算低于百万的科室级项目","\u002Ftools\u002Fhealthcare\u002Fyidu",{"free":370,"startingPrice":333,"currency":377,"billingPeriod":378,"notes":379},"CNY","一次性","官网未公开报价,需联系销售。2026-11 核对时首页只返回站点标题与少量文本,产品页返回 403,未取得价格页或产品清单正文。此类数据平台与科研服务按项目签约,金额取决于数据治理范围、专病库数量、随访年限与服务形式(平台交付或研究外包)。2026-11 核对。",[381,382,383,384,385],"把散在 HIS、LIS、PACS、病理系统里的病历抽成结构化字段,是它最核心也最难被替代的一段","专病库按病种建模,能做队列筛选、随访计划与科研数据导出,省掉临床科室自己建表的时间","真实世界研究这条线上,数据治理、统计分析、成果产出能打包,药企不用找三家拼","区域健康大数据项目经验足,卫健委侧的监管看板与指标体系有现成模板","对隐私合规的处理有专门方案,去标识化、权限隔离、数据不出院这些能写进合同","cn",7.6,{"features":389,"ease":390,"data":391,"price":392,"support":393},8.2,6.9,8.6,6.7,7.5,{"title":5,"description":369},"tools\u002Fhealthcare\u002Fyidu",[397,398,91,226],"医疗健康","医疗大数据","https:\u002F\u002Fwww.yiducloud.com.cn","医渡科技有限公司","HpLpk9-WidZsy5GhYvuuIk4k25TxEPJT-0K94HxLv8g",1016,[404,413,421],{"path":405,"toolName":406,"description":407,"score":391,"pricing":408,"vendor":411,"date":412,"category":360},"\u002Ftools\u002Fhealthcare\u002Fdxy","丁香医生","丁香医生是丁香园旗下院外健康平台,集团官网写明注册医师 450 万+,App 首次问诊 9.9 元起,科普内容有医生审稿。它适合药企做患者教育、个人问小病,不适合当医院信息系统用,也不做医保结算,问诊只是轻咨询。",{"free":373,"startingPrice":333,"currency":377,"billingPeriod":409,"notes":410},"年","C 端免费使用,问诊按次付费,App Store 官方文案写明首次问诊 9.9 元起,复诊单价由接诊医生设定。药企内容合作、医院科普项目等机构业务官网未公开标准报价,需联系销售。价格核对时间 2026-11。","丁香园","2026-11-04",{"path":414,"toolName":415,"description":416,"score":417,"pricing":418,"vendor":415,"date":420,"category":360},"\u002Ftools\u002Fhealthcare\u002Falihealth","阿里健康","阿里健康是阿里系医药与医疗平台,官网披露天猫健康 4.83 万商家、大药房 123 万 SKU、码上放心服务 7100 家流通企业。强项在商家规模与药品追溯合规,适合药企做渠道,不适合想买独立 HIS 的医院,云医院由合作方实施。",8.5,{"free":370,"startingPrice":333,"currency":377,"billingPeriod":409,"notes":419},"C 端购药与问诊按件、按次付费,无独立订阅套餐。天猫健康入驻涉及保证金与技术年费,码上放心按追溯码用量或年度服务计费,官网均未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-22",{"path":422,"toolName":423,"description":424,"score":425,"pricing":426,"vendor":423,"date":428,"category":360},"\u002Ftools\u002Fhealthcare\u002Fhaodf","好大夫在线","好大夫在线收录 10450 家医院、931617 位大夫,App 写明 28 万医生入驻、服务 8900 万患者。它是医生个人品牌的入口,问诊价格由医生定,适合副主任以上医生和找专病专家的患者。不适合急诊,入驻免费但抽成不公开,签约前要多看同城案例。",8.3,{"free":373,"startingPrice":333,"currency":377,"billingPeriod":409,"notes":427},"患者浏览医生主页、看评价免费,图文、电话、视频问诊按医生自报价付费,私人医生与优选会员为付费服务。医生入驻不收费。平台抽成比例与机构合作报价官网未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-29",1794788233267]